Share This Author
Breast cancer in China.
Challenges to effective cancer control in China, India, and Russia.
Planning cancer control in Latin America and the Caribbean.
Dietary Flaxseed Alters Tumor Biological Markers in Postmenopausal Breast Cancer
- L. Thompson, J. M. Chen, Tong Li, K. Strasser-Weippl, P. Goss
- MedicineClinical Cancer Research
- 15 May 2005
Dietary flaxseed has the potential to reduce tumor growth in patients with newly diagnosed breast cancer.
Epidemiology and pathophysiology of pregnancy-associated breast cancer: A review.
Current Status and Future Projections of Breast Cancer in Asia
The proportional contribution of Asia to the global breast cancer rates is increasing rapidly in parallel to the socioeconomic development, and the mortality-to-incidence ratios are much higher for Asia than for Western countries.
Advances in adjuvant hormonal therapy for postmenopausal women.
- K. Strasser-Weippl, P. Goss
- Medicine, BiologyJournal of clinical oncology : official journal…
- 10 March 2005
More than 40,000 breast cancer patients, most of them postmenopausal, have been treated with tamoxifen, either in the context of clinical research studies or in clinical practice.
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
Results show that outcomes in HER2+ patients with early BC not receiving anti-HER2 therapy strongly depend on HR expression, and suggest that in resource-constrained environments patients with HER2- HR- early BC should be prioritized for consideration of adjuvant anti- HER2 therapy.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
The extension of treatment with an adjuvant aromatase inhibitor to 10 years resulted in significantly higher rates of disease-free survival and a lower incidence of contralateral breast cancer than those with placebo, but the rate of overall survival was not higher with the aromat enzyme inhibitor than with placebo.